Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes

Abstract

Autoimmune muscle diseases (myositis) comprise a group of complex phenotypes influenced by genetic and environmental factors. To identify genetic risk factors in patients of European ancestry, we conducted a genome-wide association study (GWAS) of the major myositis phenotypes in a total of 1710 cases, which included 705 adult dermatomyositis, 473 juvenile dermatomyositis, 532 polymyositis and 202 adult dermatomyositis, juvenile dermatomyositis or polymyositis patients with anti-histidyl-tRNA synthetase (anti-Jo-1) autoantibodies, and compared them with 4724 controls. Single-nucleotide polymorphisms showing strong associations (P<5 × 10−8) in GWAS were identified in the major histocompatibility complex (MHC) region for all myositis phenotypes together, as well as for the four clinical and autoantibody phenotypes studied separately. Imputation and regression analyses found that alleles comprising the human leukocyte antigen (HLA) 8.1 ancestral haplotype (AH8.1) defined essentially all the genetic risk in the phenotypes studied. Although the HLA DRB1*03:01 allele showed slightly stronger associations with adult and juvenile dermatomyositis, and HLA B*08:01 with polymyositis and anti-Jo-1 autoantibody-positive myositis, multiple alleles of AH8.1 were required for the full risk effects. Our findings establish that alleles of the AH8.1 comprise the primary genetic risk factors associated with the major myositis phenotypes in geographically diverse Caucasian populations.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Parkes M, Cortes A, van Heel DA, Brown MA . Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet 2013; 14: 661–673.

    Article  CAS  Google Scholar 

  2. Ricano-Ponce I, Wijmenga C . Mapping of immune-mediated disease genes. Annu Rev Genomics Hum Genet 2013; 14: 325–353.

    Article  CAS  Google Scholar 

  3. Rider LG, Miller FW . Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 2011; 305: 183–190.

    Article  CAS  Google Scholar 

  4. Ginn LR, Lin JP, Plotz PH, Bale SJ, Wilder RL, Mbauya A et al. Familial autoimmunity in pedigrees of idiopathic inflammatory myopathy patients suggests common genetic risk factors for many autoimmune diseases. Arthritis Rheum 1998; 41: 400–405.

    Article  CAS  Google Scholar 

  5. Niewold TB, Wu SC, Smith M, Morgan GA, Pachman LM . Familial aggregation of autoimmune disease in juvenile dermatomyositis. Pediatrics 2011; 127: e1239–e1246.

    Article  Google Scholar 

  6. Scott AP, Laing NG, Mastaglia F, Needham M, Walter MC, Dalakas MC et al. Recombination mapping of the susceptibility region for sporadic inclusion body myositis within the major histocompatibility complex. J Neuroimmunol 2011; 235: 77–83.

    Article  CAS  Google Scholar 

  7. O'Hanlon TP, Carrick DM, Targoff IN, Arnett FC, Reveille JD, Carrington M et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 2006; 85: 111–127.

    Article  CAS  Google Scholar 

  8. Chinoy H, Salway F, Fertig N, Shephard N, Tait BD, Thomson W et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006; 8: R13.

    Article  Google Scholar 

  9. Trowsdale J, Knight JC . Major histocompatibility complex genomics and human disease. Annu Rev Genomics Hum Genet 2013; 14: 301–323.

    Article  CAS  Google Scholar 

  10. Horton R, Gibson R, Coggill P, Miretti M, Allcock RJ, Almeida J et al. Variation analysis and gene annotation of eight MHC haplotypes: the MHC Haplotype Project. Immunogenetics 2008; 60: 1–18.

    Article  CAS  Google Scholar 

  11. Miller FW Inflammatory myopathies: polymyositis, dermatomyositis, and related conditions. In: Koopman W, Moreland L (eds.) Arthritis and Allied Conditions, A Textbook of Rheumatology; Vol 15. Lippincott, Williams and Wilkins:: Philadelphia, 2005: 1593–1620.

    Google Scholar 

  12. Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J . Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology(Oxford) 2015; 54: 50–63.

    Article  CAS  Google Scholar 

  13. Miller FW, Cooper RG, Vencovsky J, Rider LG, Danko K, Wedderburn LR et al. Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum 2013; 65: 3239–3247.

    Article  CAS  Google Scholar 

  14. Mitchell MK, Gregersen PK, Johnson S, Parsons R, Vlahov D New York Cancer P. The New York Cancer Project: rationale, organization, design, and baseline characteristics. J Urban Health 2004; 81: 301–310.

    Article  Google Scholar 

  15. Wellcome Trust Case Control C. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661–678.

    Article  Google Scholar 

  16. Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B et al. TRAF1-C5 as a risk locus for rheumatoid arthritis—a genomewide study. N Engl J Med 2007; 357: 1199–1209.

    Article  CAS  Google Scholar 

  17. O'Hanlon TP, Miller FW . Genetic risk and protective factors for the idiopathic inflammatory myopathies. Curr Rheumatol Rep 2009; 11: 287–294.

    Article  Google Scholar 

  18. Chinoy H, Lamb JA, Ollier WE, Cooper RG . Recent advances in the immunogenetics of idiopathic inflammatory myopathy. Arthritis Res Ther 2011; 13: 216.

    Article  Google Scholar 

  19. Chinoy H, Payne D, Poulton KV, Fertig N, Betteridge Z, Gunawardena H et al. HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy. Rheumatology (Oxford) 2009; 48: 1213–1217.

    Article  CAS  Google Scholar 

  20. Pinto D, Darvishi K, Shi X, Rajan D, Rigler D, Fitzgerald T et al. Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants. Nat Biotechnol 2011; 29: 512–520.

    Article  CAS  Google Scholar 

  21. Hassan AB, Nikitina-Zake L, Sanjeevi CB, Lundberg IE, Padyukov L . Association of the proinflammatory haplotype (MICA5.1/TNF2/TNFa2/DRB1*03) with polymyositis and dermatomyositis. Arthritis Rheum 2004; 50: 1013–1015.

    Article  CAS  Google Scholar 

  22. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70: 360–374.

    Article  CAS  Google Scholar 

  23. Miller FW . Myositis-specific autoantibodies. Touchstones for understanding the inflammatory myopathies. JAMA 1993; 270: 1846–1849.

    Article  CAS  Google Scholar 

  24. Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013; 92: 223–243.

    Article  CAS  Google Scholar 

  25. Casciola-Rosen L, Mammen AL . Myositis autoantibodies. Curr Opin Rheumatol 2012; 24: 602–608.

    Article  CAS  Google Scholar 

  26. Scheet P, Stephens M . A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. Am J Hum Genet 2006; 78: 629–644.

    Article  CAS  Google Scholar 

  27. Candore G, Lio D, Colonna RG, Caruso C . Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions. Autoimmun Rev 2002; 1: 29–35.

    Article  CAS  Google Scholar 

  28. Price P, Witt C, Allcock R, Sayer D, Garlepp M, Kok CC et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev 1999; 167: 257–274.

    Article  CAS  Google Scholar 

  29. Chinoy H, Salway F, John S, Fertig N, Tait BD, Oddis CV et al. Tumour necrosis factor-alpha single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies. Rheumatology (Oxford) 2007; 46: 1411–1416.

    Article  CAS  Google Scholar 

  30. Chinoy H, Adimulam S, Marriage F, New P, Vincze M, Zilahi E et al. Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. Ann Rheum Dis 2012; 71: 961–965.

    Article  CAS  Google Scholar 

  31. Rothwell S, Cooper RG, Lamb JA, Chinoy H . Entering a new phase of immunogenetics in the idiopathic inflammatory myopathies. Curr Opin Rheumatol 2013; 25: 735–741.

    Article  CAS  Google Scholar 

  32. Kaslow RA, Shaw S . The role of histocompatibility antigens (HLA) in infection. Epidemiol Rev 1981; 3: 90–114.

    Article  CAS  Google Scholar 

  33. Xie Z, Chang C, Zhou Z . Molecular mechanisms in autoimmune type 1 diabetes: a critical review. Clin Rev Allergy Immunol 2014; 47: 174–192.

    Article  CAS  Google Scholar 

  34. Candore G, Campagna AM, Cuppari I, Di CD, Mineo C, Caruso C . Genetic control of immune response in carriers of the 8.1 ancestral haplotype: correlation with levels of IgG subclasses: its relevance in the pathogenesis of autoimmune diseases. Ann NY Acad Sci 2007; 1110: 151–158.

    Article  CAS  Google Scholar 

  35. Candore G, Balistreri CR, Campagna AM, Colombo A, Cuppari I, Di-Carlo D et al. Genetic control of immune response in carriers of ancestral haplotype 8.1: the study of chemotaxis. Ann NY Acad Sci 2006; 1089: 509–515.

    Article  Google Scholar 

  36. Olivares M, Laparra JM, Sanz Y . Host genotype, intestinal microbiota and inflammatory disorders. Br J Nutr 2013; 109: S76–S80.

    Article  CAS  Google Scholar 

  37. Olivares M, Neef A, Castillejo G, Palma GD, Varea V, Capilla A et al. The HLA-DQ2 genotype selects for early intestinal microbiota composition in infants at high risk of developing coeliac disease. Gut 2014; 64: 406–417.

    Article  Google Scholar 

  38. Bohan A, Peter JB, Bowman RL, Pearson CM . Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977; 56: 255–286.

    Article  CAS  Google Scholar 

  39. Targoff IN, Trieu EP, Miller FW . Reaction of anti-OJ autoantibodies with components of the multi- enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest 1993; 91: 2556–2564.

    Article  CAS  Google Scholar 

  40. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559–575.

    Article  CAS  Google Scholar 

  41. Rich SS, Concannon P, Erlich H, Julier C, Morahan G, Nerup J et al. The Type 1 Diabetes Genetics Consortium. Ann NY Acad Sci 2006; 1079: 1–8.

    Article  CAS  Google Scholar 

  42. Erlich HA, Lohman K, Mack SJ, Valdes AM, Julier C, Mirel D et al. Association analysis of SNPs in the IL4R locus with type I diabetes. Genes Immun 2009; 10: S33–S41.

    Article  CAS  Google Scholar 

  43. Concannon P, Chen WM, Julier C, Julier C, Morahan G, Akolkar B et al. Genome-wide scan for linkage to type 1 diabetes in 2,496 multiplex families from the Type 1 Diabetes Genetics Consortium. Diabetes 2009; 58: 1018–1022.

    Article  CAS  Google Scholar 

  44. Purcell S, Cherny SS, Sham PC . Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003; 19: 149–150.

    Article  CAS  Google Scholar 

  45. Evangelou E, Ioannidis JP . Meta-analysis methods for genome-wide association studies and beyond. Nat Rev Genet 2013; 14: 379–389.

    Article  CAS  Google Scholar 

  46. Begum F, Ghosh D, Tseng GC, Feingold E . Comprehensive literature review and statistical considerations for GWAS meta-analysis. Nucleic Acids Res 2012; 40: 3777–3784.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported in part by: the Intramural Program of the NIH, National Institute of Environmental Health Sciences (NIEHS Z01ES101074); European Community’s FP6, AutoCure LSHB CT-2006-018661; Myositis UK; Arthritis Research UK (18474 and 20164); The Cure JM Foundation; the European Science Foundation in the framework of the Research Networking Programme European Myositis Network (EuMyoNet); Association Francaise Contre Les Myopathies (AFM), the National Institute for Health Research Biomedical Research Centre at ICH/GOSH; the National Institute for Health Research Manchester Musculoskeletal Biomedical Research Unit; the Wellcome Trust; Action Medical UK; Great Ormond Street Children’s Charity; the National Institute for Health Research Translational Research Collaboration on rare diseases; and the Swedish Research Council. The Czech cohort was partially supported by the Ministry of Health, Czech Republic (No. 00023728).

We are indebted to Dr Javier Martin (Instituto de Parasitología y Biomedicina, Granada, Spain) for supplying Spanish control data, Dr Peter Novota (Institute of Rheumatology, Prague, Czech Republic) for supplying Czech controls and Dr Lars Alfredsson (Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden) for Swedish control data. We thank Dr Younghun Han (Dartmouth College) for statistical support, Miss Hazel Platt and Mrs Fiona Marriage (Centre for Integrated Genomic Medical Research, University of Manchester, Manchester, UK) and Drs Maryam Dastmalchi and Eva Jemseby (Karolinska Institutet, Stockholm, Sweden) for technical support, Mr Paul New (Salford Royal Foundation Trust, Salford, UK) for ethical and technical support, Sue Edelstein (Image Associates, Inc., Durham, NC) for graphics support and Lisa Maroski for assistance in manuscript preparation.

We thank Dr Elaine Remmers (National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD) and Dr Douglas Bell (National Institute of Environmental Health Sciences, Research Triangle Park, NC) of the National Institutes of Health for their critical review of the manuscript.

We thank the other study investigators of the Myositis Genetics Consortium: Drs Christopher Denton (Royal Free Hospital, London, UK), David Hilton-Jones (John Radcliffe Hospital, Oxford, UK), Patrick Kiely (St George's Hospital, London, UK), Paul H. Plotz, Mark Gourley (National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD), and Hemlata Varsani (University College London, London, UK).

We thank members of the UK Adult Onset Myositis Immunogenetic Collaboration who recruited and enrolled subjects: Drs Yasmeen Ahmed (Llandudno General Hospital), Raymond Armstrong (Southampton General Hospital), Robert Bernstein (Manchester Royal Infirmary), Carol Black (Royal Free Hospital, London), Simon Bowman (University Hospital, Birmingham), Ian Bruce (Manchester Royal Infirmary), Robin Butler (Robert Jones & Agnes Hunt Orthopaedic Hospital, Oswestry), John Carty (Lincoln County Hospital), Chandra Chattopadhyay (Wrightington Hospital), Easwaradhas Chelliah (Wrightington Hospital), Fiona Clarke (James Cook University Hospital, Middlesborough), Peter Dawes (Staffordshire Rheumatology Centre, Stoke on Trent), Joseph Devlin (Pinderfields General Hospital, Wakefield), Christopher Edwards (Southampton General Hospital), Paul Emery (Academic Unit of Musculoskeletal Disease, Leeds), John Fordham (South Cleveland Hospital, Middlesborough), Alexander Fraser (Academic Unit of Musculoskeletal Disease, Leeds), Hill Gaston (Addenbrooke's Hospital, Cambridge), Patrick Gordon (King's College Hospital, London), Bridget Griffiths (Freeman Hospital, Newcastle), Harsha Gunawardena (Frenchay Hospital, Bristol), Frances Hall (Addenbrooke's Hospital, Cambridge), Beverley Harrison (North Manchester General Hospital), Elaine Hay (Staffordshire Rheumatology Centre, Stoke on Trent), Lesley Horden (Dewsbury District General Hospital), John Isaacs (Freeman Hospital, Newcastle), Adrian Jones (Nottingham University Hospital), Sanjeet Kamath (Staffordshire Rheumatology Centre, Stoke on Trent), Thomas Kennedy (Royal Liverpool Hospital), George Kitas (Dudley Group Hospitals Trust, Birmingham), Peter Klimiuk (Royal Oldham Hospital), Sally Knights (Yeovil District Hospital, Somerset), John Lambert (Doncaster Royal Infirmary), Peter Lanyon (Queen's Medical Centre, Nottingham), Ramasharan Laxminarayan (Queen's Hospital, Burton Upon Trent), Bryan Lecky (Walton Neuroscience Centre, Liverpool), Raashid Luqmani (Nuffield Orthopaedic Centre, Oxford), Jeffrey Marks (Steeping Hill Hospital, Stockport), Michael Martin (St James University Hospital, Leeds), Dennis McGonagle (Academic Unit of Musculoskeletal Disease, Leeds), Neil McHugh (Royal National Hospital for Rheumatic Diseases, Bath), Francis McKenna (Trafford General Hospital, Manchester), John McLaren (Cameron Hospital, Fife), Michael McMahon (Dumfries & Galloway Royal Infirmary, Dumfries), Euan McRorie (Western General Hospital, Edinburgh), Peter Merry (Norfolk & Norwich University Hospital, Norwich), Sarah Miles (Dewsbury & District General Hospital, Dewsbury), James Miller (Royal Victoria Hospital, Newcastle), Anne Nicholls (West Suffolk Hospital, Bury St Edmunds), Jennifer Nixon (Countess of Chester Hospital, Chester), Voon Ong (Royal Free Hospital, London), Katherine Over (Countess of Chester Hospital, Chester), John Packham (Staffordshire Rheumatology Centre, Stoke on Trent), Nicolo Pipitone (King's College Hospital, London), Michael Plant (South Cleveland Hospital, Middlesborough), Gillian Pountain (Hinchingbrooke Hospital, Huntington), Thomas Pullar (Ninewells Hospital, Dundee), Mark Roberts (Salford Royal Foundation Trust), Paul Sanders (Wythenshawe Hospital, Manchester), David Scott (King's College Hospital, London), David Scott (Norfolk & Norwich University Hospital, Norwich), Michael Shadforth (Staffordshire Rheumatology Centre, Stoke on Trent), Thomas Sheeran (Cannock Chase Hospital, Cannock, Staffordshire), Arul Srinivasan (Broomfield Hospital, Chelmsford), David Swinson (Wrightington Hospital), Lee-Suan Teh (Royal Blackburn Hospital, Blackburn), Michael Webley (Stoke Manderville Hospital, Aylesbury), Brian Williams (University Hospital of Wales, Cardiff), and Jonathan Winer (Queen Elizabeth Hospital, Birmingham).

We thank members of the UK Juvenile Dermatomyositis Research Group who recruited and enrolled subjects: Dr Kate Armon, Mr Joe Ellis-Gage, Ms Holly Roper, Ms Vanja Briggs, and Ms Joanna Watts (Norfolk and Norwich University Hospitals); Dr Liza McCann, Mr Ian Roberts, Dr Eileen Baildam, Ms Louise Hanna, and Ms Olivia Lloyd (The Royal Liverpool Children’s Hospital, Alder Hey, Liverpool); Dr Phil Riley and Ms Ann McGovern (Royal Manchester Children’s Hospital, Manchester); Dr Clive Ryder, Mrs Janis Scott, Mrs Beverley Thomas, Professor Taunton Southwood, and Dr Eslam Al-Abadi (Birmingham Children’s Hospital, Birmingham); Dr Sue Wyatt, Mrs Gillian Jackson, Dr Tania Amin, Dr Mark Wood, Dr Vanessa Van Rooyen, and Ms Deborah Burton (Leeds General Infirmary, Leeds); Dr Joyce Davidson, Dr Janet Gardner-Medwin, Dr Neil Martin, Ms Sue Ferguson, Ms Liz Waxman, and Mr Michael Browne (The Royal Hospital for Sick Children, Yorkhill, Glasgow); Dr Mark Friswell, Professor Helen Foster, Mrs Alison Swift, Dr Sharmila Jandial, Ms Vicky Stevenson, Ms Debbie Wade, Dr Ethan Sen, Dr Eve Smith, Ms Lisa Qiao and Mr Stuart Watson (Great North Children’s Hospital, Newcastle); Dr Helen Venning, Dr Rangaraj Satyapal, Mrs Elizabeth Stretton, Ms Mary Jordan, Dr Ellen Mosley, Ms Anna Frost, Ms Lindsay Crate, and Dr Kishore Warrier (Queens Medical Centre, Nottingham); Professor Lucy Wedderburn, Dr Clarissa Pilkington, Dr N. Hasson, Mrs Sue Maillard, Ms Elizabeth Halkon, Ms Virginia Brown, Ms Audrey Juggins, Dr Sally Smith, Mrs Sian Lunt, Ms Elli Enayat, Mrs Hemlata Varsani, Miss Laura Kassoumeri, Miss Laura Beard, Miss Katie Arnold, Mrs Yvonne Glackin, Miss Stephanie Simou and Dr Beverley Almeida (Great Ormond Street Hospital, London); Dr Kevin Murray (Princess Margaret Hospital, Perth, Western Australia); Dr John Ioannou and Ms Linda Suffield (University College London Hospital); Dr Muthana Al-Obaidi, Ms Helen Lee, Ms Sam Leach and Ms Helen Smith (Sheffield’s Children’s Hospital); and Dr Nick Wilkinson, Ms Emma Inness, Ms Eunice Kendall and Mr David Mayers (Oxford University Hospitals).

We thank the following members of the US Childhood Myositis Heterogeneity Study Group who recruited and enrolled subjects: Drs Barbara S. Adams (University of Michigan, Ann Arbor, MI), Catherine A. Bingham (Hershey Medical Center, Hershey, PA), Gail D. Cawkwell (All Children's Hospital, St Petersburg, FL), Terri H. Finkel (Children's Hospital of Philadelphia, Philadelphia, PA), Steven W. George (Ellicott City, MD), Harry L. Gewanter (Richmond, VA), Ellen A. Goldmuntz (Children's National Medical Center, Washington, DC), Donald P. Goldsmith (St Christopher's Hospital for Children, Philadelphia, PA), Michael Henrickson (Children's Hospital, Madera, CA), Lisa Imundo (Columbia University, New York, NY), Ildy M. Katona (Uniformed Services University, Bethesda, MD), Carol B. Lindsley (University of Kansas, Kansas City), Chester P. Oddis (University of Pittsburgh, Pittsburgh, PA), Judyann C. Olson (Medical College of Wisconsin, Milwaukee), David Sherry (Children's Hospital of Philadelphia, Philadelphia, PA), Scott A. Vogelgesang (Walter Reed Army Medical Center, Washington, DC), Carol A. Wallace (Children's Medical Center, Seattle, WA), Patience H. White (George Washington University, Washington, DC) and Lawrence S. Zemel (Connecticut Children's Hospital, Hartford).

Disclaimer

The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the institutions with which they are affiliated.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to F W Miller.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Genes and Immunity website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miller, F., Chen, W., O'Hanlon, T. et al. Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. Genes Immun 16, 470–480 (2015). https://doi.org/10.1038/gene.2015.28

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gene.2015.28

This article is cited by

Search

Quick links